There is one clinical trial.
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
Description: All Cause Mortality at 28 daysMeasure: Mortality at 28 days Time: 28 days after enrollment
Description: To assess the effect of Pulmozyme® on the severity of respiratory failure, systemic inflammatory response, and multi-organ failure.Measure: Systemic Therapeutic Response Time: 5 days after enrollment
Description: Proportion of patients alive and free of invasive mechanical ventilation at 28 days invasive mechanical ventilation at 28 daysMeasure: Respiratory Response Time: 28 days
Description: Proportion of patients alive and discharged from the ICU at 28 days discharged from the ICU at 28 daysMeasure: Legnth of ICU Stay Time: 28 days
Description: Proportion of patients alive and discharged from the hospital at 28 daysMeasure: Legnth of Hospital Stay Time: 28 days
Description: Alive, respiratory failure-free days at 28 daysMeasure: Respiratory Response Time: 28 days
Description: Pulmonary Function Ratio at 5 daysMeasure: Pulmonary Function Time: 5 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports